Navigation Links
HPV-associated cancer incidence rates point to needed efforts to increase HPV vaccination coverage
Date:1/7/2013

Despite the decline in cancer death rates in the U.S., there is an increase in incidence rates for cancers associated with human papillomavirus (HPV) infection and more efforts are needed to increase HPV vaccination coverage levels to prevent the occurrence of these cancers in the future according to a study published January 7 in the Journal of the National Cancer Institute.

The American Cancer Society (ACS), the Centers for Disease Control and Prevention (CDC), the National Cancer Institute (NCI), and the North American Association of Central Cancer Registries (NAACCR) annually provide updates on trends in cancer incidence and death rates in the United States. This year's report highlighted trends in incidence rates for HPV associated cancers and HPV vaccination coverage levels. Two HPV vaccines (bivalent and quadrivalent) have been shown to protect against most cervical cancers in women and one vaccine (quadrivalent) also protects against genital warts and cancers of the anus, vagina and vulva. There is no data available on vaccine efficacy for prevention HPV-associated cancers of the oropharynx.

In order to assess trends in HPV-associated cancer incidence rates and HPV vaccination coverage levels, Ahmedin Jemal, D.V.M., Ph.D., Surveillance Research Program, American Cancer Society, Atlanta, GA., and colleagues examined cancer incidence data reported by the CDC, and NCI, through NAACCR, as well as cancer mortality data from the CDC. The researchers determined trends in age-standardized incidence and death rates for all cancers combined and for the leading cancers among men and women, while HPV vaccination coverage levels during 2008 and 2010 and the prevalence of Papanicolaou (Pap) testing during 2010 were obtained from national surveys.

During 2000-2009, the researchers found that overall cancer death rates in the U.S. continue to decrease (including for lung, colorectal, female breast, and prostate cancers), but that death rates have increased for cancers of the liver, pancreas, uterine corpus, and melanoma of the skin among males. The incidence rates for these cancers continued to increase as well, including for some cancers associated with HPV infection. Nationally, 32.0% of females aged 13-17 years had received three doses of the HPV vaccine in 2010 showing the necessity for increased efforts to increase HPV vaccination coverage. "Continued monitoring of incidence and mortality trends for all cancers is warranted to inform cancer prevention and control policies and programs," the authors conclude.

In an accompanying editorial, Marc Brisson, Ph.D., Centre de recherche du CHU de Qubec, Hpital Saint-Sacrement, Qubec, Canada, and colleagues write that HPV vaccination efforts should be focused on females because it's been predicted to be the most effective way to ensure population-level vaccine effectiveness. "Finding ways to increasing vaccine uptake is a key priority for HPV-related public health research in the United States."


'/>"/>

Contact: Zachary Rathner
Zachary.Rathner@oup.com
301-841-1286
Journal of the National Cancer Institute
Source:Eurekalert

Related medicine news :

1. Costly breast cancer screenings dont add up to better outcomes
2. Centralization to fewer surgeons results in better survival after esophageal cancer surgery
3. Some HPV-Linked Cancers Rising in U.S.: Report
4. Costly Breast Cancer Screenings May Not Help Seniors: Study
5. US Drug Watchdog Now Urges Any Diabetic Who Used the Diabetes Drug Actos and Now Have Been Diagnosed with Bladder Cancer to Call The Johnson Law Group-ASAP
6. Cancer Genome Institute at Fox Chase among first to offer clinical blueprint of cancer genes
7. Ovarian cancer stem cell study puts targeted therapies within reach
8. How prostate cancer therapies compare by cost and effectiveness
9. Mayo Clinic researchers find new molecule to target in pancreatic cancer treatment
10. Scientists discover how deadly skin cancer spreads into other parts of the body
11. Some Complain of Shorter Penis After Prostate Cancer Treatment: Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... ... , ... i2i Systems, an early innovator and developer of population health management ... KLAS report, Population Health Management 2015: How Far Can Your Vendor Take You? ... (PHM). The latest KLAS Report, leveraging over 200 user interviews, shines a light ...
(Date:2/8/2016)... ... February 08, 2016 , ... Brenntag Specialties, Inc.(BSI) ... Food & Beverage and Dietary Supplement market segments across ... and USA geographies east of the Rocky Mountains since 2012. Consistent performance ...
(Date:2/8/2016)... ... February 08, 2016 , ... Brenton Engineering ... pouches, bags, and flow wrapped products at WestPack 2015, February 9-11, in Anaheim, ... step up to semi-automatic or fully-automatic case packing with a small footprint, rugged, ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... serving the greater Venice, FL area, has initiated a fundraiser for a two ... accident just four days after Christmas. To support this beautiful child who is ...
(Date:2/8/2016)... ... , ... FileHold's document management software has been implemented by ... environment for FileHold software that is pay per user subscription-based and also does ... FileHold web services API. DocuSyst also advises clients on fully functioning back up ...
Breaking Medicine News(10 mins):
(Date:2/9/2016)... 2016  The Parenteral Drug Association, Inc. (PDA), ... manufacturing sterile drug products, today announced the publication ... – With link to Comparison Spreadsheet. The ... U.S. FDA, the EU, the Pharmaceutical Inspection Convention/Scheme ... --> --> PDA,s Global Sterile ...
(Date:2/8/2016)... LONDON , Feb.8, 2016 Cardiovascular ... Summary GlobalData,s Medical Devices sector report, ... 2015" provides an overview of Cardiovascular Surgery Devices ... --> The report provides comprehensive ... of the products at various stages of development. ...
(Date:2/8/2016)... and FAIRFIELD, N.J. , Feb. 8, ... Pharmaceuticals, Inc. (Medimetriks) today announced that they have entered ... commercialization rights for OPA-15406 in the U.S. and ... manufacturing rights.  OPA-15406 is a topical, non-steroidal phosphodiesterase IV ... --> --> In ...
Breaking Medicine Technology: